Hormonal diseases

146 trials 57 recruiting

Filter these 146 trials by phase, country and sponsor.

Open in Search →

An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency Recruiting

2023-504020-25-00 Idiopathic Growth Hormone Deficiency 4 2023-12-28
The CORTAD study Recruiting

2024-512888-31-00 Primary adrenal insufficiency (PAI) 11 2023-08-03
INVITED trial Recruiting

2022-500906-17-01 Type 1 diabetes 4 2023-03-21
HIsTological and CLinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. (HITCLIF) Recruiting

2023-504943-15-00 Cancer(colon cancer stage II-III, rectal cancer, and br 4 2022-08-19
Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors Recruiting

2024-513007-14-00 locally advanced or metastatic, well-differentiated gas 3 2022-03-24
Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome Recruiting

2024-518001-18-00 Turner syndrome 6 2021-11-29
Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women with Turner Syndrome Recruiting

2024-518557-42-00 Turner syndrome 6 2021-11-29
Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome Recruiting

2024-518932-34-00 patients with adrenal incidentalomas and subclinical/mi 6 2020-09-22
Studying the effects of intramuscular testosterone supplementation compared with placebo on liver fat content in obese men with low testoste… Recruiting

2023-509819-87-00 hypogonadism, T2DM, prediabetes, overweight, obesity 6 2019-07-18
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic pros… Recruiting

2024-519516-14-01 Metastatic prostate cancer, Prostate cancer 4 2019-04-15
Treatment of Graves´ ophthalmopathy with diclofenak or simvastatin Recruiting

2024-517833-42-00 Graves´ ophthalmopathy 10 2017-12-11
A Phase 1/2 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM Ended

2024-519005-35-00 Type 2 Diabetes Mellitus 7 2026-03-09
Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, open label, dose titration, proof of concept study (Silycus… Ended

2024-518869-99-00 Cushing's disease 4 2025-11-17
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended

2023-503383-17-01 Female androgenetic alopecia 5 2024-10-10
Phase 3, Randomized, Open-Label Study of ARV-471 (PF-07850327) Plus Palbociclib vs Letrozole Plus Palbociclib in Participants With ER(+)/HER… Ended

2022-500545-24-00 ER + /HER 2 - Advanced Breast Cancer 5 2023-10-04
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controll… Ended

2022-502038-23-00 Type 1 diabetes 4 2023-08-25
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
A research study looking at how safe somapacitan is and how well it works in children who need help to grow – REAL 9 Ended

2022-501055-87-01 Noonan syndrome 5 2023-05-18
Impact of peri-operative tEstosterone levels oN Functional and oncological Outcomes following RadiCal prostatEctomy Ended

2024-511340-29-02 Late-onset hypogonadism 5 2022-12-14
Ixekizumab Diabetes Intervention Trial (I-DIT) Ended

2023-508588-58-00 Diabetes type 1 4 2022-10-25
A research study to compare somapacitan once a week with Norditropin® once a day in children who need help to grow Ended

2023-506927-27-00 Children with short stature either born small for gesta 5 2022-08-29
The RESCUE study Ended

2024-518272-30-00 Glucocorticoid induced adrenal insufficiency 6 2022-06-01
Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia Ended

2023-509170-33-00 Classic Congenital Adrenal Hyperplasia (CAH) 5 2021-11-23